ReviewAnnals of the American Thoracic Society2014
Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
Review in Annals of the American Thoracic Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02262871 (Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy.Cell & bioscience · 2021Review
- Let-7b-5p in vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic sensitivity ofProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Protease inhibitors elicit anti-inflammatory effects in CF mice with Pseudomonas aeruginosa acute lung infection.Clinical and experimental immunology · 2021Article
- Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.American journal of respiratory and critical care medicine · 2020Article
- Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable.Frontiers in pediatrics · 2020Review
- Altered Stool Microbiota of Infants with Cystic Fibrosis Shows a Reduction in Genera Associated with Immune Programming from Birth.Journal of bacteriology · 2019Article
- Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis.Annals of the American Thoracic Society · 2017Observational
- Review
- Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?American journal of respiratory and critical care medicine · 2017Review
- β-Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells.Frontiers in pharmacology · 2017Article
- An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research.American journal of respiratory and critical care medicine · 2016Article
- Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.Pediatric pulmonology · 2015Article
- The Evolution of Cystic Fibrosis Care.Chest · 2015Review
- Reply: primary and secondary prevention of chronic obstructive pulmonary disease: where to next?American journal of respiratory and critical care medicine · 2014Article
- Executive Summary: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Annals of the American Thoracic Society · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Cystic fibrosis (CF) is a life-limiting, monogenic disorder characterized by chronic sinopulmonary and gastrointestinal involvement. Progressive pulmonary disease leads to death in the majority of patients. Despite its well-defined molecular basis related to defects in the cystic fibrosis transmembrane conductance regulator anion transport channel, there are large gaps in our understanding of the origin of CF lung disease. Disease has been shown to be present in infancy, and there is mounting evidence that abnormalities begin in utero. Heterogeneity of clinical presentations and severity suggest that many factors involved in lung disease have yet to be fully elucidated. Although new advances in therapeutic treatments have shown promise in delaying disease progression, the prevention of pulmonary disease at its origin (primary prevention) should be a key goal of CF care. The objective of this workshop was to (1) review our understanding of the origins of CF lung disease, (2) determine gaps in the knowledge base that are most significant and most likely to enable prevention of CF lung disease, and (3) prioritize new research questions that will promote pulmonary health in both CF and other childhood lung diseases. The goal of this report is to provide recommendations for future research that will improve our understanding of pulmonary development in health and disease, improve outcome measures and biomarkers for early lung disease, and determine therapeutic targets and strategies to prevent the development of lung disease in children with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.